Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.46 |
| ▸ | GRM5 | P41594 | 5/20 | 0.43 |
| ▸ | SCD5 | Q86SK9 | 3/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6987335 | 0.86 | ADAM17 (0.48) | HSP90AA1HSP90AB1ADAM17GRM5SCD5 | |
| SCHEMBL6987252 | 0.81 | HSD11B1 (0.50) | SCD5 | |
| SCHEMBL6987244 | 0.81 | HCRTR1 (0.50) | SCD5 | |
| SCHEMBL2477683 | 0.77 | ALDH1A1 (0.49) | HSP90AA1HSP90AB1 | |
| SCHEMBL6987311 | 0.74 | FABP4 (0.45) | HSP90AA1HSP90AB1SCD5 | |
| SCHEMBL6990139 | 0.73 | SCD5 (0.53) | SCD5 | |
| SCHEMBL6990102 | 0.72 | PROKR1 (0.50) | — | |
| SCHEMBL6989431 | 0.72 | HCRTR2 (0.44) | GRM5SCD5 | |
| SCHEMBL31318774 | 0.70 | ADAM17 (0.53) | ADAM17GRM5 | |
| SCHEMBL6987290 | 0.70 | HCRTR1 (0.48) | SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | FABP4, FABP1, FABP3 | HSP90AA1 293/4885HSP90AB1 283/4885ADAM17 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.